ES2318869T3 - Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion. - Google Patents
Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion. Download PDFInfo
- Publication number
- ES2318869T3 ES2318869T3 ES98907531T ES98907531T ES2318869T3 ES 2318869 T3 ES2318869 T3 ES 2318869T3 ES 98907531 T ES98907531 T ES 98907531T ES 98907531 T ES98907531 T ES 98907531T ES 2318869 T3 ES2318869 T3 ES 2318869T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- binder
- composition according
- active ingredients
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000006185 dispersion Substances 0.000 title claims description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 26
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 238000003860 storage Methods 0.000 claims abstract description 7
- 239000011230 binding agent Substances 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 21
- 239000013590 bulk material Substances 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 16
- 238000007639 printing Methods 0.000 claims description 15
- 239000011159 matrix material Substances 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 235000010356 sorbitol Nutrition 0.000 claims description 8
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 7
- 239000001904 Arabinogalactan Substances 0.000 claims description 7
- 229920000189 Arabinogalactan Polymers 0.000 claims description 7
- 235000019312 arabinogalactan Nutrition 0.000 claims description 7
- 238000012377 drug delivery Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 238000000151 deposition Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 4
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008376 breath freshener Substances 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 229960005008 doxylamine succinate Drugs 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000000133 nasal decongestant Substances 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 210000003079 salivary gland Anatomy 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000006068 taste-masking agent Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 229960001985 dextromethorphan Drugs 0.000 claims 1
- 229960000520 diphenhydramine Drugs 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 26
- 230000000717 retained effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 21
- 239000012530 fluid Substances 0.000 description 19
- 239000000428 dust Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000002483 medication Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 229920003080 Povidone K 25 Polymers 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000010146 3D printing Methods 0.000 description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003079 Povidone K 17 Polymers 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 3
- 238000011960 computer-aided design Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920003170 water-soluble synthetic polymer Polymers 0.000 description 2
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- 241000070918 Cima Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000014174 Oesophageal disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- -1 ethanol or methanol Chemical compound 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3888397P | 1997-02-20 | 1997-02-20 | |
| US3828497P | 1997-02-20 | 1997-02-20 | |
| US38284P | 1997-02-20 | ||
| US38883P | 1997-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2318869T3 true ES2318869T3 (es) | 2009-05-01 |
Family
ID=26715043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98907531T Expired - Lifetime ES2318869T3 (es) | 1997-02-20 | 1998-02-20 | Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6471992B1 (enExample) |
| EP (1) | EP0973507B1 (enExample) |
| JP (3) | JP4563516B2 (enExample) |
| AT (1) | ATE421318T1 (enExample) |
| AU (1) | AU736912B2 (enExample) |
| CA (1) | CA2281473C (enExample) |
| DE (1) | DE69840495D1 (enExample) |
| ES (1) | ES2318869T3 (enExample) |
| WO (1) | WO1998036738A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4563516B2 (ja) * | 1997-02-20 | 2010-10-13 | マサチューセッツ インスティテュート オブ テクノロジー | 迅速分散性を示す投与剤形、その使用法並びにその製造方法 |
| WO1999059544A2 (en) * | 1998-05-18 | 1999-11-25 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
| US6284270B1 (en) * | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| EP1301177A2 (en) * | 2000-07-10 | 2003-04-16 | Therics, Inc. | Method and materials for controlling migration of binder liquid in a powder |
| HRP20031057B1 (hr) * | 2001-06-28 | 2013-05-31 | Ucb Farchim Sa, Z.I. Planchy | Tableta koja sadrži cetirizin i pseudoefedrin |
| EA005537B1 (ru) * | 2001-07-10 | 2005-04-28 | Тева Фармасьютикал Индастриес Лтд. | Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата |
| US20030099708A1 (en) * | 2001-10-29 | 2003-05-29 | Therics, Inc | Printing or dispensing a suspension such as three-dimensional printing of dosage forms |
| JP4845340B2 (ja) * | 2001-10-29 | 2011-12-28 | マサチューセッツ インスティテュート オブ テクノロジー | 三次元プリント投薬形態のような物品の一軸圧縮のためのシステムおよび方法 |
| DE60323482D1 (de) | 2002-05-06 | 2008-10-23 | Massachusetts Inst Technology | Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken |
| MXPA05005528A (es) | 2002-11-26 | 2006-04-05 | Alk Abello As | Producto farmaceutico de alergeno. |
| ES2378452T3 (es) | 2004-09-21 | 2012-04-12 | Hypnion, Inc. | �?cido 3-[4-(dibenzo[b,f][1,4]oxazepin-11-il)-piperazin-1-il]-2,2¿dimetil-propanoico para usarlo en el tratamiento de trastornos del sueño |
| US7829000B2 (en) * | 2005-02-25 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Core-shell solid freeform fabrication |
| US8187659B2 (en) | 2006-05-02 | 2012-05-29 | Jerry Robertson Real Estate Llc | Solid medicament dosage form consumption aid |
| ES2500165T3 (es) | 2006-06-29 | 2014-09-30 | Kinex Pharmaceuticals, Llc | Composiciones de biarilo y métodos para modular una cascada de quinasas |
| ES2842334T3 (es) | 2007-10-20 | 2021-07-13 | Athenex Inc | Composiciones farmacéuticas para modular una cascada de cinasas y métodos de uso de las mismas |
| US12186426B2 (en) | 2009-10-30 | 2025-01-07 | Ix Biopharma Ltd. | Solid dosage form |
| EP2493457B1 (en) | 2009-10-30 | 2017-08-09 | IX Biopharma Ltd | Fast dissolving solid dosage form |
| ES2634551T3 (es) * | 2010-04-03 | 2017-09-28 | Praful Doshi | Métodos para revestir una lente de contacto |
| US8692001B2 (en) | 2010-10-27 | 2014-04-08 | Dynamix Pharmaceuticals Ltd. | Sulfonamides for the modulation of PKM2 |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| US8722636B2 (en) | 2011-01-31 | 2014-05-13 | New Market Pharmaceuticals, LLC | Animal treatments |
| WO2012122370A2 (en) | 2011-03-08 | 2012-09-13 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| ITMI20110792A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia. |
| ITMI20110793A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
| ITMI20110791A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri in grado di metabolizzare gli ossalati. |
| US20120302609A1 (en) | 2011-05-25 | 2012-11-29 | Dynamix Pharmaceuticals Ltd. | Pyrazolines for the Modulation of PKM2 |
| JP6054379B2 (ja) | 2011-06-07 | 2016-12-27 | クレベクセル・ファーマＣｌｅｖｅｘｅｌ Ｐｈａｒｍａ | キナーゼをモジュレートするための組成物および方法 |
| ITMI20111718A1 (it) | 2011-09-23 | 2013-03-24 | Probiotical Spa | Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali. |
| US9245061B2 (en) * | 2012-04-25 | 2016-01-26 | Shapeways, Inc. | Weight-based identification of three dimensional printed parts |
| AU2012379005B2 (en) | 2012-05-02 | 2017-12-21 | Newmarket Pharmaceuticals Llc | Pharmaceutical compositions for direct systemic introduction |
| IN2014DN11205A (enExample) | 2012-06-20 | 2015-10-02 | Eutropics Pharmaceuticals Inc | |
| CN105263907B (zh) | 2012-08-30 | 2018-11-20 | 阿西纳斯公司 | 作为蛋白质酪氨酸激酶调节剂的n-(3-氟苄基)-2-(5-(4-吗啉代苯基)吡啶-2-基)乙酰胺 |
| WO2014116770A1 (en) | 2013-01-23 | 2014-07-31 | Arx, Llc | Production of unit dose constructs |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| ES2761407T3 (es) | 2013-03-15 | 2020-05-19 | Aprecia Pharmaceuticals LLC | Forma de dosificación rápidamente dispersable de topiramato |
| EP2968354B1 (en) * | 2013-03-15 | 2019-11-13 | Aprecia Pharmaceuticals LLC | Rapidly dispersible dosage form of oxcarbazepine |
| HK1216513A1 (zh) * | 2013-03-15 | 2016-11-18 | 阿普雷奇亚制药有限责任公司 | 包含左乙拉西坦的快速分散劑型 |
| WO2014176389A1 (en) | 2013-04-24 | 2014-10-30 | Temple University - Of The Commonwealth System Of Higher Education | Solid dosage form containing arabinogalactan |
| ITMI20130793A1 (it) | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti. |
| JP6233996B2 (ja) | 2013-08-16 | 2017-11-22 | ザ エクスワン カンパニー | ３次元印刷される金属鋳造用鋳型及び同鋳型の製造方法 |
| US20160243621A1 (en) | 2013-10-17 | 2016-08-25 | The Exone Company | Three-Dimensional Printed Hot Isostatic Pressing Containers and Processes for Making Same |
| EP3086921B1 (en) * | 2013-12-23 | 2019-07-31 | The Exone Company | Methods and systems for three-dimensional printing utilizing a jetted-particle binder fluid |
| ES2745763T3 (es) | 2013-12-23 | 2020-03-03 | The Exone Co | Métodos y sistemas para la impresión en tres dimensiones utilizando múltiples fluidos aglutinantes |
| US11001048B2 (en) | 2013-12-23 | 2021-05-11 | The Exone Company | Method of three-dimensional printing using a multi-component build powder |
| EP3137113A4 (en) * | 2014-04-30 | 2017-03-22 | Blaesi, Aron H. | Melt-processed polymeric cellular dosage form |
| US20170120329A1 (en) | 2014-05-29 | 2017-05-04 | The Exone Company | Process for Making Nickel-Based Superalloy Articles by Three-Dimensional Printing |
| WO2016011098A2 (en) | 2014-07-17 | 2016-01-21 | The Exone Company | Methods and apparatuses for curing three-dimensional printed articles |
| PT3220891T (pt) | 2014-11-21 | 2019-10-31 | Biohaven Pharm Holding Co Ltd | Formulação sublingual de riluzol |
| EP3227109B1 (en) | 2014-12-03 | 2020-08-19 | The Exone Company | Process for making densified carbon articles by three dimensional printing |
| EP3302442B1 (en) | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| EP3108874A1 (en) * | 2015-06-26 | 2016-12-28 | TRB Chemedica AG | Ophthalmologic pharmaceutical composition |
| WO2017075096A1 (en) * | 2015-10-26 | 2017-05-04 | Blaesi Aron H | Solid dosage form immediate drug release and apparatus and method for manufacture thereof |
| US11129798B2 (en) | 2016-08-19 | 2021-09-28 | Aron H. Blaesi | Fibrous dosage form |
| EP3429564A1 (en) * | 2016-03-18 | 2019-01-23 | Grünenthal GmbH | Combination of drugs having different potency |
| MA45334A (fr) | 2016-03-24 | 2019-01-30 | Probiotical Spa | Composition bactérienne d'acide lactique pour le traitement d'infections vaginales bactériennes par gardnerella vaginalis et, éventuellement, d'infections fongiques concurrentes |
| ES2992002T3 (es) * | 2016-04-06 | 2024-12-05 | Astellas Pharma Inc | Moldeo tridimensional de elución rápida, filamento para moldeo tridimensional de elución rápida y material para moldeo tridimensional de elución rápida |
| EP3981392A1 (en) | 2016-05-05 | 2022-04-13 | Triastek, Inc. | Controlled release dosage form |
| HRP20240617T1 (hr) | 2016-05-20 | 2024-07-19 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| CN110023310B (zh) | 2016-08-12 | 2024-05-10 | 阿西纳斯公司 | 用于调节激酶级联的联芳组合物和方法 |
| US11040491B2 (en) | 2016-10-19 | 2021-06-22 | Shapeways, Inc. | Systems and methods for identifying three-dimensional printed objects |
| CA3045043A1 (en) | 2016-12-31 | 2018-07-05 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| US12102721B2 (en) | 2017-01-26 | 2024-10-01 | Triastek, Inc. | Dosage forms of controlled release at specific gastrointestinal sites |
| US11602502B2 (en) | 2017-02-24 | 2023-03-14 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3D) printing a pharmaceutical tablet |
| ES2958616T3 (es) | 2017-03-08 | 2024-02-12 | Cinrx Pharma Llc | Formulaciones farmacéuticas de floroglucinol y trimetilfloroglucinol |
| US10435576B2 (en) | 2017-05-26 | 2019-10-08 | Infinite Material Solutions, Llc | Water soluble polymer compositions |
| RS66277B1 (sr) | 2017-11-12 | 2025-01-31 | Biohaven Therapeutics Ltd | Primena prolekova riluzola za lečenje ataksija |
| CN108066302B (zh) * | 2017-12-28 | 2020-09-11 | 无限极（中国）有限公司 | 一种快速分散固体制剂的制备方法及制备的快速分散固体制剂 |
| US10350822B1 (en) | 2018-01-09 | 2019-07-16 | Triastek Inc. | Dosage forms with desired release profiles and methods of designing and making thereof |
| CN116270513A (zh) | 2018-01-09 | 2023-06-23 | 南京三迭纪医药科技有限公司 | 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型 |
| DE102018107585B3 (de) * | 2018-03-29 | 2019-03-28 | Universität Rostock | Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen |
| CN115154440A (zh) | 2018-06-27 | 2022-10-11 | 比奥克斯塞尔医疗股份有限公司 | 含右美托咪定的膜制剂及其制造方法 |
| US11278501B2 (en) | 2018-10-15 | 2022-03-22 | Aprecia Pharmaceuticals LLC | Method and system for forming a dosage form within a packaging |
| WO2020104837A1 (en) | 2018-11-21 | 2020-05-28 | Rosemont Pharmaceuticals Limited | Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability |
| US12103229B2 (en) * | 2019-03-15 | 2024-10-01 | Ricoh Company, Ltd. | Jettable temporary binders to create removable support materials |
| JP7287032B2 (ja) | 2019-03-20 | 2023-06-06 | 株式会社リコー | シート、シート積層体、医薬品、シートの製造方法、及びシート積層体の製造方法 |
| AU2020277668A1 (en) * | 2019-05-21 | 2021-11-25 | Dfe Pharma Gmbh & Co. Kg | Lactose powder bed three dimensional printing |
| WO2021016112A2 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| EP3789015A1 (en) * | 2019-09-05 | 2021-03-10 | Universität Innsbruck | Fast consolidating compounds |
| TWI734309B (zh) * | 2019-12-19 | 2021-07-21 | 水星生醫股份有限公司 | 滲透性噴塗製作藥錠裝置 |
| US12371581B2 (en) | 2020-03-25 | 2025-07-29 | Infinite Material Solutions, Llc | High performance water soluble polymer compositions |
| MX2022016117A (es) | 2020-06-26 | 2023-04-05 | Aprecia Pharmaceuticals LLC | Tabletas rapidamente orodispersables que tienen una cavidad interior. |
| US20230390193A1 (en) | 2020-10-30 | 2023-12-07 | Triastek, Inc. | Gastroretentive pharmaceutical dosage form |
| WO2022155564A1 (en) | 2021-01-18 | 2022-07-21 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
| WO2024108082A1 (en) | 2022-11-18 | 2024-05-23 | Aprecia Pharmaceuticals LLC | Orodispersive dosage forms containing droxidopa |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642903A (en) | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
| US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
| US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| FR2647343B1 (fr) * | 1989-05-24 | 1994-05-06 | Rhone Poulenc Sante | Nouvelle forme pharmaceutique poreuse et sa preparation |
| US5206025A (en) * | 1989-05-24 | 1993-04-27 | Rhone-Poulenc Sante | Porous pharmaceutical form and its preparation |
| EP0418596A3 (en) * | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
| US5204055A (en) | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
| US5578322A (en) | 1990-11-30 | 1996-11-26 | Yamanouchi Pharmaceutical Co., Ltd. | Quick release coated preparation |
| ES2081564T3 (es) | 1991-01-31 | 1996-03-16 | Texas Instruments Inc | Metodo y sistema para la fabricacion, controlada por ordenador, de objetos tridimensionales a partir de datos de ordenador. |
| ATE138563T1 (de) * | 1991-12-20 | 1996-06-15 | Pfizer | Poröse geformte abgabevorrichtung und verfahren zur herstellung derselbe |
| JP2521612B2 (ja) * | 1992-05-20 | 1996-08-07 | ウエイ・ミン・フアーマシユーテイカル・マニユフアクチヤリング・カンパニー・リミテツド | 直接錠剤形成助剤 |
| US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| US5380473A (en) | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
| DE4303846A1 (de) * | 1993-02-10 | 1994-08-11 | Merck Patent Gmbh | Verfahren zur Herstellung einer S-Ibuprofen enthaltenden Tablette |
| JP3233638B2 (ja) | 1993-07-09 | 2001-11-26 | アール．ピー． シェーラー コーポレイション | 凍結乾燥された薬投与形状物の製造方法 |
| US6176874B1 (en) | 1993-10-18 | 2001-01-23 | Masschusetts Institute Of Technology | Vascularized tissue regeneration matrices formed by solid free form fabrication techniques |
| US6280771B1 (en) | 1997-02-20 | 2001-08-28 | Therics, Inc. | Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof |
| US5490962A (en) | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
| US5503785A (en) | 1994-06-02 | 1996-04-02 | Stratasys, Inc. | Process of support removal for fused deposition modeling |
| US5633021A (en) | 1994-10-19 | 1997-05-27 | Bpm Technology, Inc. | Apparatus for making a three-dimensional article |
| US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
| US5560927A (en) * | 1995-07-28 | 1996-10-01 | Isp Investments Inc. | Co-processing method for making a free-flowing compressible powder and tablet therefrom |
| US5653925A (en) * | 1995-09-26 | 1997-08-05 | Stratasys, Inc. | Method for controlled porosity three-dimensional modeling |
| JP4563516B2 (ja) | 1997-02-20 | 2010-10-13 | マサチューセッツ インスティテュート オブ テクノロジー | 迅速分散性を示す投与剤形、その使用法並びにその製造方法 |
| DE19940944B4 (de) * | 1999-08-31 | 2006-10-12 | Grünenthal GmbH | Retardierte, orale, pharmazeutische Darreichungsformen |
-
1998
- 1998-02-20 JP JP53687898A patent/JP4563516B2/ja not_active Expired - Lifetime
- 1998-02-20 ES ES98907531T patent/ES2318869T3/es not_active Expired - Lifetime
- 1998-02-20 DE DE69840495T patent/DE69840495D1/de not_active Expired - Lifetime
- 1998-02-20 AU AU63314/98A patent/AU736912B2/en not_active Ceased
- 1998-02-20 EP EP98907531A patent/EP0973507B1/en not_active Expired - Lifetime
- 1998-02-20 AT AT98907531T patent/ATE421318T1/de not_active IP Right Cessation
- 1998-02-20 WO PCT/US1998/003256 patent/WO1998036738A1/en not_active Ceased
- 1998-02-20 CA CA002281473A patent/CA2281473C/en not_active Expired - Lifetime
- 1998-02-20 US US09/027,183 patent/US6471992B1/en not_active Expired - Lifetime
-
2002
- 2002-07-19 US US10/200,029 patent/US9463160B2/en not_active Expired - Fee Related
-
2009
- 2009-05-11 JP JP2009114753A patent/JP5091910B2/ja not_active Expired - Lifetime
- 2009-11-09 JP JP2009256374A patent/JP2010120938A/ja not_active Withdrawn
-
2012
- 2012-02-09 US US13/369,473 patent/US9114072B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20030133975A1 (en) | 2003-07-17 |
| JP2001512488A (ja) | 2001-08-21 |
| AU736912B2 (en) | 2001-08-02 |
| AU6331498A (en) | 1998-09-09 |
| EP0973507A1 (en) | 2000-01-26 |
| CA2281473A1 (en) | 1998-08-27 |
| US9463160B2 (en) | 2016-10-11 |
| ATE421318T1 (de) | 2009-02-15 |
| WO1998036738A1 (en) | 1998-08-27 |
| DE69840495D1 (de) | 2009-03-12 |
| JP5091910B2 (ja) | 2012-12-05 |
| EP0973507A4 (en) | 2006-08-23 |
| EP0973507B1 (en) | 2009-01-21 |
| JP4563516B2 (ja) | 2010-10-13 |
| US20120207929A1 (en) | 2012-08-16 |
| US6471992B1 (en) | 2002-10-29 |
| CA2281473C (en) | 2007-01-16 |
| JP2009215305A (ja) | 2009-09-24 |
| US9114072B2 (en) | 2015-08-25 |
| JP2010120938A (ja) | 2010-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2318869T3 (es) | Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion. | |
| JP2009215305A6 (ja) | 迅速分散性を示す投与剤形、その使用法並びにその製造方法 | |
| Gauri et al. | Fast dissolving drug delivery and its technologies. | |
| Ghosh et al. | A review on new generation orodispersible tablets and its future prospective | |
| KR950010144B1 (ko) | 펄스(pulse)식 약제 전달용 투약장치의 제조방법 | |
| ES2272344T3 (es) | Preparacion laminar multicapas a base de polimeros hidrofilos para la liberacion rapida de principios activos. | |
| PT97739B (pt) | Processo para a preparacao de uma pastilha medicamentosa mascavel e para mascarar o sabor de medicamentos | |
| US20060093679A1 (en) | Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve | |
| WO2008127669A1 (en) | Bilayer lyophilized pharmaceutical compositions and methods of making and using same | |
| PL211301B1 (pl) | Tabletka wielowarstwowa dyspergowalna w ustach oraz sposób jej wytwarzania | |
| Beri et al. | Development of fast disintegration tablets as oral drug delivery system-A review | |
| Jain et al. | A review-formulation & development of orodispersible tablet | |
| US11986558B2 (en) | Drug delivery system | |
| Nandhini et al. | Dispersible tablets: A review | |
| Vora et al. | Oral dispersible tablet: A popular growing technology | |
| Chandan et al. | Orally disintegrating tablets: A Review | |
| Amipara et al. | Oral disintirating tablet of antihypertensive drug | |
| AU8731801A (en) | Dosage from exhibiting rapid disperse properties, methods of use and process for the manufacture of same | |
| PA et al. | A review: On sublingual tablets | |
| Kumar et al. | Fast dissolving tablets: patient compliance dosage forms | |
| US20110165254A1 (en) | Drug Delivery Using Fine Fiber Encapsulation | |
| Rai et al. | Sublingual Route for the Systemic Delivery of Drugs | |
| Jhansi et al. | A REVIEW ON ORAL DISINTEGRATING TABLETS | |
| Savane et al. | AN OVERVIEW ON FAST DISSOLVING TABLET | |
| Alagarsamy et al. | Review on Fast Dissolving Tablets Technology and Superdisintegrants |